Ensysce Biosciences vs Ocugen
Ensysce Biosciences and Ocugen are similar in size: $5.1m and $4.4m of revenue in their latest fiscal years. Ocugen grew faster (8.8% against -2.8%). Ensysce Biosciences kept more of each dollar of sales as profit: a net margin of -200.8% against -1537.4%.
| Latest fiscal year | Ensysce BiosciencesENSC, 2025 | OcugenOCGN, 2025 |
|---|---|---|
| Revenue | $5.1m | $4.4m |
| Revenue growth | -2.8% | 8.8% |
| Net income | −$10.2m | −$67.8m |
| Operating margin | -202.1% | -1425.7% |
| Net margin | -200.8% | -1537.4% |
| Return on equity | — | — |
| Free cash flow | −$7.9m | −$57.1m |
| Cash | $4.3m | $18.6m |
| Total debt | $306,708 | $31.5m |
| Debt to equity | 9.5% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 116 |
| Market value | $5.9m | $253m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 2 buys, 0 sales | 1 buys, 4 sales |